已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

11q23 balanced chromosome aberrations in treatment‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop†

染色体易位 生物 急性白血病 内科学 骨髓增生异常综合症 核型 白血病 胃肠病学 肿瘤科 染色体 免疫学 癌症研究 基因 遗传学 医学 骨髓
作者
Clara D. Bloomfield,Kellie J. Archer,Krzysztof Mrózek,Debra M. Lillington,Yasuhiko Kaneko,David R. Head,Paola Dal Cin,Susana C. Raimondi
出处
期刊:Genes, Chromosomes and Cancer [Wiley]
卷期号:33 (4): 362-378 被引量:162
标识
DOI:10.1002/gcc.10046
摘要

Abstract Among 511 patients with therapy‐related myelodysplastic syndrome or acute leukemia (t‐MDS/t‐AL) and balanced chromosome aberrations, 162 (32%) had translocations involving 11q23. The recurring translocation partners were 9p22 (48%), 19p13.3 (11%), 19p13.1 (10%), 4q21 (9%), 6q27 (6%), 1p32 (2%), 16p13.1 (2%), 10p13 (1%), and 17q25 (1%); in 9%, the translocations were seen only once. The remaining 349 patients were divided into five subgroups based on the balanced aberration: 21q22, inv(16), t(15;17), Rare, and Unique aberrations. Patients in the 11q23 subgroup had a sole cytogenetic abnormality more often than those in the 21q22, inv(16), Rare, and Unique subgroups, and a complex karyotype or −5/del(5q) and/or −7/del(7q) less often than patients in the 21q22, Rare, and Unique subgroups. Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t‐MDS/t‐AL diagnosis, except when compared with the inv(16) subgroup. The 11q23 subgroup demonstrated a younger age at t‐MDS/t‐AL diagnosis, but this finding was not significant when patients with AL as their primary diagnosis were excluded. Survival from the time of diagnosis of t‐MDS/t‐AL was significantly shorter for the 11q23 subgroup compared with that of the 21q22, inv(16), and t(15;17) subgroups (median 8 vs. 14, 28, and 29 months, respectively). Inferior survival occurred even though 11q23 patients were younger and more often received blood or marrow transplantation (BMT). Even among patients receiving BMT, 11q23 patients had a shorter median survival (9 vs. 12–31 months for the other subgroups). However, among 11q23 patients, those receiving BMT survived longer, with 1‐ and 5‐year survivals of 43% and 18% compared with 23% and 7% for patients not transplanted. With regard to prior therapy, 11q23 patients, compared with other patients, received radiotherapy less often as their sole therapy and chemotherapy more often. They had received VP16, methotrexate, 6MP/6TG, L ‐asparaginase, daunorubicin, cytarabine, and VM26 more often, likely attributed to the high frequency of AL as their primary disease. More patients in the 11q23 subgroup had received doxorubicin, except in comparison with the 21q22 subgroup; more vincristine, except in comparison with the Rare and Unique subgroups; and more prednisone, except in comparison with the Unique subgroup. Patients in the 11q23 subgroup more often received alkylating agents (AAs) (86% vs. 59–82% for the other subgroups), and topoisomerase II inhibitors (TIs) (84% vs. 49–75%), and they more often reported exposure to AAs plus TIs without radiotherapy (33% vs. 12–21%), except in comparison with the 21q22 subgroup (36%). We performed a multivariate analysis to determine whether the adverse survival of 11q23 patients compared to other Workshop patients was explained by factors other than the presence of the 11q23 abnormality. Covariates in the final model were the five cytogenetic subgroup indicators, where the 11q23 subgroup was the referent ( P < 0.0001); age at t‐MDS/t‐AL ( P = 0.0036); previous exposure to lomustine ( P < 0.0001) and mitoxantrone ( P = 0.0225); BMT for t‐MDS/t‐AL ( P = 0.0006); and karyotype complexity ( P = 0.0114). The risk of death for 11q23 patients relative to patients in the 21q22, inv(16), t(15;17), and Unique subgroups was significant, even after adjustment for other risk factors (relative risks 2.3, 3.6, 3.1, and 1.5, respectively; P < 0.0001 for the first three comparisons and P = 0.0125 for the last). When a multivariable model was constructed, excluding patients with AL or MDS as their primary diagnosis, the relative risk of death for 11q23 patients was significantly higher than that of all five other cytogenetic subgroups. We conclude that among t‐MDS/t‐AL patients with balanced aberrations, 11q23 translocations are an independent adverse risk factor. Although BMT is the current therapy of choice, new treatment is required. © 2002 Wiley‐Liss, Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
潘佳琪完成签到 ,获得积分10
刚刚
hyl完成签到,获得积分10
2秒前
PeterPan发布了新的文献求助10
2秒前
杨好圆完成签到,获得积分10
4秒前
medvc完成签到,获得积分10
5秒前
5秒前
5秒前
5秒前
5秒前
6秒前
9秒前
10秒前
10秒前
禾伙人发布了新的文献求助10
12秒前
12秒前
13秒前
猪四郎发布了新的文献求助10
13秒前
14秒前
晚风发布了新的文献求助10
14秒前
nonoke完成签到 ,获得积分10
14秒前
15秒前
内向的尔风完成签到 ,获得积分10
15秒前
pero发布了新的文献求助10
15秒前
悠哈不错完成签到 ,获得积分10
17秒前
17秒前
17秒前
17秒前
深情安青的应助被科研通管家采纳,获得30
18秒前
爆米花的应助被一坤年练习生采纳,获得10
18秒前
18秒前
18秒前
新新新新新发顶刊完成签到 ,获得积分10
18秒前
18秒前
Shirong_Peng发布了新的文献求助10
19秒前
星河完成签到 ,获得积分10
20秒前
哼哼哈嘿发布了新的文献求助30
20秒前
JUAN123发布了新的文献求助10
20秒前
杨涵完成签到,获得积分10
21秒前
隐形曼青的应助被梭梭采纳,获得10
21秒前
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189908
求助须知:如何正确求助?哪些是违规求助? 9577068
关于积分的说明 21851352
捐赠科研通 7787862
什么是DOI,文献DOI怎么找? 3435817
关于科研通互助平台的介绍 2559861
邀请新用户注册赠送积分活动 2482718